A dopamine receptor antagonist
Related Products
Labeled Version(s)
28617Pimozide-d4
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Pimozide

Item No. 16222

Technical Information
Formal Name
1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one
CAS Number
2062-78-4
Synonyms
  • NSC 170984
  • R 6238
Molecular Formula
C28H29F2N3O
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 3 mg/ml
λmax
283 nm
SMILES
FC1=CC=C(C(CCCN2CCC(N3C(NC4=C3C=CC=C4)=O)CC2)C5=CC=C(F)C=C5)C=C1
InChi Code
InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
InChi Key
YVUQSNJEYSNKRX-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    Pimozide is a dopamine receptor antagonist (Kis = 2.4, 0.3, and 1.8 nM for D2, D3, and D4 receptors, respectively).1 It also binds to eight additional receptors (Kds = 25-3,100 nM for the human receptors) and inhibits the voltage-gated sodium channel Nav1.2 and the voltage-gated potassium channel Kv11.1 (IC50s = 42 and 340 nM, respectively).2,3,4 Pimozide (0.5, 1, and 2 mg/kg) decreases the number of licks and reduces fluid intake of a sweetened solution in rats.5 It decreases the number of threats and attacks and increases immobility time in the neutral arena aggression test, indicating increased passiveness, in male mice when administered at a dose of 0.75 mg/kg for 10 days.6 Formulations containing pimozide have been used in the treatment of Tourette syndrome.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Burstein, E.S., Ma, J., Wong, S., et alIntrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther. 315(3), 1278-1287 (2005).

    2. Richelson, E., and Souder, T. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci. 68(1), 29-39 (2000).

    3. Roufos, I., Hay, S., and Schwarz, R.D. A structure-activity relationship study of novel phenylacetamides which are sodium channel blockers. J. Med. Chem. 39(7), 1514-1520 (1996).

    4. Lau, J.F., Jeppesen, C.B., Rimvall, K., et alUreas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg. Med. Chem. Lett. 16(20), 5303-5308 (2006).

    5. Xenakis, S., and Sclafani, A. The effects of pimozide on the consumption of a palatable saccharin-glucose solution in the rat. Pharmacol. Biochem. Behav. 15(3), 435-442 (1980).

    6. Navarro, J.F., Velasco, R., and Manzaneque, J.M. Acute and subchronic effects of pimozide on isolation-induced aggression in male mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 24(1), 131-142 (2000).